Company news

Share this article:
According to an internal memo, Pfizer is planning to end manufacturing of heart disease medications, Forbes reported, while also scaling back development of anemia, osteoporosis, liver, muscle, obesity and peripheral artery disease treatments. The company will instead focus on five therapeutic areas: Alzheimer's; diabetes, immune disorders and inflammation; cancer; pain and mental illness.

In an effort to control costs, GlaxoSmithKline may cut as many as 850 R&D jobs in the US and UK, according to a Wall Street Journal report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.